GLUE

Monte Rosa TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

MRT-8102 has shown deep inflammatory-biomarker reductions, MRT-2359 produced encouraging early oncology data, and cash into 2029 gives Monte Rosa time to hit multiple de-risking milestones; if one or more 2026 readouts validate, the shares could re-rate toward the 33.8 median target.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +9.1.

What can break

GFORCE-1 and follow-on MRT-8102 Phase 2 studies could fail to reproduce the observed inflammatory signal or raise safety concerns.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $18.50 · Bull $33.80 · Bear $8.50

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-06-06 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $33.17

Why

Momentum91 · Δ7d +9.1

Value49 · Δ7d -0.3

Sentiment27 · Δ7d -7.6

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+9.1

Δ21d

+28.6

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.3

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-7.6

Δ21d

-9.2

Why this grade

Composite grade C. Momentum 91.3 / Value 48.8 / Sentiment 27.1

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$1.98B

Beta

1.61

Shares Out

84.48M

P/E (TTM)

57.5

P/S (TTM)

5.17

P/FCF (TTM)

6.47

Rev YoY

-95.0%

EPS YoY

-178.8%

Gross Margin

+80.6%

Op Margin

+4.7%

Net Debt

-$337.91M

Current Ratio

9.54

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology